Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net loss	$ (18,036,619)	$ (6,719,222)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	25,342	8,268
Loss on sale or disposal of assets	6,761	1,127
Stock-based compensation expense	1,391,068	594,175
Common stock issued for advisory services	1,409,363	0
Abandonment of in-process research and development intangible asset	951,000	0
Change in deferred income taxes	(364,796)	0
Settlement of litigation matter	2,500,000	0
Non-cash interest expense	38,446	165,329
Amortization of debt issuance costs and debt discount	0	147,150
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	319,545	(29,739)
Accounts payable, accrued expenses and other liabilities	991,625	647,584
Net cash used in operating activities	(10,768,265)	(5,185,328)
Cash flows provided by investing activities:
Purchases of property and equipment	(2,331)	(40,291)
Maturities of certificates of deposit	0	2,500,000
Cash received in reverse merger transaction	8,500,602	0
Net cash provided by investing activities	8,498,271	2,459,709
Cash flows provided by financing activities:
Proceeds from the issuance of convertible debt	1,880,000	2,401,602
Payment of offering costs	(54,346)	(15,310)
Net cash provided by financing activities	1,825,654	2,386,292
Net decrease in cash and cash equivalents	(444,340)	(339,327)
Cash and cash equivalents at beginning of period	1,997,192	2,336,519
Cash and cash equivalents at end of period	1,552,852	1,997,192
Supplemental disclosure of non-cash investing and financing activities:
Offering costs in accounts payable	126,110	0
Conversion of convertible notes and related accrued interest into common stock	711,495	19,700,976
Consideration in connection with RestorGenex Corporation merger transaction	$ 21,261,000	$ 0